FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ODell William F 		2. Issuer Name and Ticker or Trading Symbol

DUSA PHARMACEUTICALS INC [ DUSA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Exec. VP Sales and Marketing
(Last)          (First)          (Middle)

C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

12/20/2012
(Street)

WILMINGTON, MA 01887
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   12/20/2012     U    53560   D $8.00   0   D    
Common Stock   (1) 12/20/2012     U    219150   D $8.00   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-qualified Stock Options   $6.90   12/20/2012     D         50000    4/17/2007   4/16/2016   Common Stock   50000     (2) 0   (2) D    
Non-qualified Stock Options   $3.37   12/20/2012     D         25000    3/20/2008   3/20/2014   Common Stock   25000     (2) 0   (2) D    
Non-qualified Stock Options   $2.20   12/20/2012     D         19500    5/9/2009   5/9/2015   Common Stock   19500     (2) 0   (2) D    
Non-qualified Stock Options   $1.22   12/20/2012     D         75100    3/13/2010   3/13/2016   Common Stock   75100     (2) 0   (2) D    
Non-qualified Stock Options   $1.65   12/20/2012     D         85000    3/5/2011   3/4/2017   Common Stock   85000     (2) 0   (2) D    

Explanation of Responses:
( 1)  These shares are restricted shares. Pursuant to the Agreement and Plan of Merger, dated as of November 8, 2012, by and among, Sun Pharmaceutical Industries Limited as assigned to Caraco Pharmaceutical Laboratories, Ltd., Caraco Acquisition Corporation and DUSA Pharmaceuticals, Inc. (the "Merger Agreement"), immediately prior to the date and time the merger becomes effective, each restricted share that is then outstanding and unvested shall immediately vest and become nonforfeitable, all restrictions and conditions applicable thereto shall lapse, and each restricted share shall be treated in the same manner as each other share of Company Common Stock in the merger and is cancelled in exchange for the right to receive cash payment for each such restricted share of $8.00.
( 2)  Pursuant to the Merger Agreement, each in-the-money stock option, whether vested or unvested, that is outstanding immediately prior to the Acceptance Time shall become fully vested immediately prior to the Acceptance Time, and be cancelled as of the Acceptance Time in exchange for the right to receive at such time a lump sum cash payment of an amount equal to (i) the Offer Price less (ii) the exercise price payable in respect of each such share of Company Common Stock issuable under such option, net of applicable taxes, if any, with respect to such option.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
ODell William F
C/O DUSA PHARMACEUTICALS, INC.
25 UPTON DRIVE
WILMINGTON, MA 01887

Exec. VP Sales and Marketing

Signatures
/s/ William O'Dell 12/20/2012
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Davis Select US Equity (NASDAQ:DUSA)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more Davis Select US Equity Charts.
Davis Select US Equity (NASDAQ:DUSA)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more Davis Select US Equity Charts.